Dupont Capital Management’s Puma Biotechnology PBYI Stock Holding History

Dupont Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-65,242	Closed	-$188K	–	1723
2022 Q1	$188K	Sell	65,242 -5,770	-8%	-$14.9K	0.01%	1072
2021 Q4	$216K	Buy	+71,012	New	+$308K	0.01%	1086
2018 Q3	–	Sell	-41,560	Closed	-$2.46M	–	1015
2018 Q2	$2.46M	Buy	41,560 +6,947	+20%	+$403K	0.06%	300
2018 Q1	$2.35M	Buy	34,613 +28,636	+479%	+$2.14M	0.06%	310
2017 Q4	$591K	Buy	+5,977	New	+$669K	0.01%	626
2016 Q4	–	Sell	-11,177	Closed	-$749K	–	856
2016 Q3	$749K	Buy	+11,177	New	+$565K	0.02%	515
2015 Q2	–	Sell	-4,060	Closed	-$959K	–	607
2015 Q1	$959K	Hold	4,060	–	–	0.02%	453
2014 Q4	$768K	Sell	4,060 -920	-18%	-$204K	0.01%	508
2014 Q3	$1.19M	Sell	4,980 -21,117	-81%	-$4.34M	0.02%	427
2014 Q2	$1.72M	Buy	26,097 +14,180	+119%	+$1.01M	0.03%	402
2014 Q1	$1.24M	Buy	+11,917	New	+$1.4M	0.02%	462

Other funds holding PBYI

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dupont Capital Management's PBYI Position: Q2 2022 in Review

Dupont Capital Management sold out of Puma Biotechnology (PBYI) in Q2 2022, closing a stake of 65,242 shares — an estimated $188K sold.

Dupont Capital Management first reported a position in PBYI in Q1 2014 and held it in 11 quarters. The position peaked at $2.46M in Q2 2018. 88 funds tracked by Wall St. Rank hold PBYI as of Q2 2022.

Dupont Capital Management reported no remaining Puma Biotechnology position as of Q2 2022 after selling out during the quarter.
Dupont Capital Management sold 65,242 Puma Biotechnology shares in Q2 2022, an estimated $188K.
Dupont Capital Management first reported a position in Puma Biotechnology in Q1 2014 and held it in 11 quarters.
Dupont Capital Management's Puma Biotechnology position peaked at $2.46M in Q2 2018.
88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2022.

Based on Dupont Capital Management's 13F filing for Q2 2022, filed 26 Jul 2022.